Table 2

Comparison of demographic data between EPS group and non-EPS group

Demographic dataEPS group
Non-EPS group
StatisticsSignificant (P values)
Age40.8 (16.8)37.3 (14.0)t=−2.610.01**
Gender (female)104 (50.7%)204 (42.9%)X2=3.720.054
Age of onset25.1 (9.3)25.5 (9.0)t=0.760.446
Illness duration15.8 (12.1)11.7 (12.1)Z=3.410.001***
Years since first prescribed antipsychotics10.6 (12.0)14.4 (15.2)Z=3.10.002
High D2 receptor antagonistic effect antipsychotics95 (44.6%)185 (38.9%)X2=3.420.064
Low and medium D2 receptor antagonistic effect antipsychotics109 (53.4%)290 (61.1%)
Atypical antipsychotics monotherapy114 (55.9%)313 (65.9%)
Atypical antipsychotics polytherapy72 (35.3%)141 (29.7%)X2=8.520.014*
Typical antipsychotics and atypical antipsychotics polytherapy18 (8.8%)21 (4.4%)
Mood stabiliser18 (8.8%)22 (4.6%)X2=4.520.033*
Antidepressants12 (5.9%)24 (5.1%)X2=0.1960.658
  • *p≤0.0; **p≤0.001; ***p≤0.0.

  • EPS, extrapyramidal symptoms.